Abstract
Found in the skins of red fruits, including grapes, resveratrol (RES) is a polyphenolic compound with cancer chemopreventive activity. Because of this activity, it has gained interest for scientific investigations. RES inhibits tumor growth and progression by targeting mitochondria-dependent or -independent pathways. However, further investigations are needed to explore the underlying mechanisms.The present study is focused on examining the role of RES-induced, mitochondria-mediated, caspase-independent apoptosis of prostate cancer cells, namely transgenic adenocarcinoma of mouse prostate (TRAMP) cells. These cells were exposed to RES for various times, and cell killing, cell morphology, mitochondrial membrane potential (Δψm), expression of Bax and Bcl2 proteins, the role of caspase-3, and DNA fragmentation were analyzed.TRAMP cells exposed to RES showed decreased cell viability, altered cell morphology, and disrupted Δψm, which led to aberrant expression of Bax and Bcl2 proteins. Furthermore, since the caspase-3 inhibitor, z-VAD-fmk (benzyloxycarbonyl-valine-alanine-aspartic acid-fluoromethyl ketone), had no appreciable impact on RES-induced cell killing, the killing was evidently caspase-independent. In addition, RES treatment of TRAMP-C1, TRAMP-C2, and TRAMP-C3 cells caused an appreciable breakage of genomic DNA into low-molecular-weight fragments.These findings show that, in inhibition of proliferation of TRAMP cells, RES induces mitochondria-mediated, caspase-independent apoptosis. Therefore, RES may be utilized as a therapeutic agent to control the proliferation and growth of cancer cells.
Highlights
In Western populations, prostate cancer is the second leading cause of death in men older than 65 years of age [1,2,3,4,5,6]
We examined the effects of RES on mitochondria-mediated, caspase-independent apoptosis in transgenic adenocarcinoma of mouse prostate (TRAMP-C1, TRAMP-C2, and TRAMP-C3) cells
Further analysis revealed that RES (100 μM) treatment resulted in a significantly greater (*P
Summary
In Western populations, prostate cancer is the second leading cause of death (after heart disease) in men older than 65 years of age [1,2,3,4,5,6]. It arises through the change of pre-neoplastic lesions into adenocarcinomas, and thereafter progresses to metastatic disease [6,7,8,9]. Androgenindependent prostate cancer cells do not undergo apoptosis www.impactjournals.com/oncotarget [14,15,16,17]. In view of these results, advanced therapies that target the proliferation of both androgen-dependent and -independent prostate cancer cells are needed
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have